<p>Interview with Ahmad Awada, MD, PhD, author of <a href= "http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.0237"> Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial</a>, and Mark D. Pegram, MD, author of <a href= "http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.0238"> Neratinib in ERBB2-Positive Brain Metastases</a></p>

Interview with Ahmad Awada, MD, PhD, author of Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial, and Mark D. Pegram, MD, author of Neratinib in ERBB2-Positive Brain Metastases

<p>Interview with Ahmad Awada, MD, PhD, author of <a href="http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.0237" rel="noopener noreferrer"> Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial</a>, and Mark D. Pegram, MD, author of <a href="http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.0238" rel="noopener noreferrer"> Neratinib in ERBB2-Positive Brain Metastases</a></p>

Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

Share Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer

Sign up to save your podcasts

Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer

Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer

More shows like JAMA Oncology Author Interviews

NEJM This Week

JAMA Clinical Reviews

Journal of Clinical Oncology (JCO) Podcast

JAMA Author Interviews

ASCO Daily News

The Daily

JAMA Pediatrics Editors' Summary

Up First from NPR

JAMA Psychiatry Author Interviews

JAMA Neurology Author Interviews

JAMA Cardiology Author Interviews

JAMA Dermatology Author Interviews

JAMA Internal Medicine Author Interviews

JAMA Ophthalmology Author Interviews

JAMA Otolaryngology–Head Neck Surgery Author Interviews

ASCO Guidelines

JAMAevidence The Rational Clinical Examination

JAMA Pediatrics Author Interviews

JAMA Medical News

JAMAevidence Users' Guides to the Medical Literature

JAMAevidence Care at the Close of Life

JAMA Network Open Conversations

Coronavirus (COVID-19) Q

JAMAevidence JAMA Guide to Statistics and Methods

The Rest Is History

JAMA Health Forum Conversations

Bad Rap: The Case Against Diddy